Encouraged by the acquisition of biotechnology company Prosensa by BioMarin Pharmaceutical, CureDuchenne has announced that it will continue to support Prosensa’s drug development efforts for DMD. CureDuchenne, a national nonprofit organization that is dedicated to finding a cure and reducing patients’ burden of suffering from the disease, has been supporting Prosensa for several years, as well as several other research projects.
“CureDuchenne has been a dedicated supporter of Prosensa since our company’s inception,” explained the Chief Executive Officer of Prosensa, Hans Schikan. “CureDuchenne’s funding came at critical times during our drug development process and their longtime commitment has been of enormous value to the company. The transaction with BioMarin will enhance our mission by bringing innovative therapies to patients across the world as quickly as possible.”
The organization will continue to fund Prosensa’s research based on BioMarin Pharmaceutical’s decision to continue developing and studying new medication for the treatment of Duchenne muscular dystrophy. BioMarin brings to the effort a proven expertise in the orphan disease space, having worked with regulatory authorities all over the world to receive approval for a series of new drugs.
“Our commitment to finding treatments for Duchenne is unwavering” added the CureDuchenne’s Founder and CEO, Debra Miller. “We have been there every step of the way for Prosensa and are encouraged that BioMarin will continue this effort that will hopefully lead to approval of drisapersen and a pipeline of other follow on exons.”
The collaborative work between CureDuchenne and Prosensa began more than 10 years ago. The organization has not only provided funding that supported the development of DMD drug drisapersen to its current stage as a drug in the revision process for a New Drug Application, but also has collaborated on awareness and funding campaigns for the disease as well. Most recently, CureDuchenne and Prosensa were invited to present their collaborative project at the 6th annual Partnering for Cures event, a conference that brought together about 1,000 medical research leaders, investors, and decision-makers to enhance partnerships and accelerate and improve the outcomes from research on the disease.